The Effect of Soy Phytoestrogen Supplementation on Thyroid Status and Cardiovascular Risk Markers in Patients with Subclinical Hypothyroidism: A Randomized, Double-Blind, Crossover Study

Department of Academic Endocrinology, Diabetes and Metabolism, Hull York Medical School, Hull HU3 2JZ, United Kingdom.
The Journal of Clinical Endocrinology and Metabolism (Impact Factor: 6.31). 02/2011; 96(5):1442-9. DOI: 10.1210/jc.2010-2255
Source: PubMed

ABSTRACT There is concern whether soy phytoestrogens may affect thyroid function. If true, soy phytoestrogens may be expected to have a greater impact in subjects with subclinical hypothyroidism.
The primary aim was to determine the effect of soy phytoestrogen supplementation on thyroid function, with a secondary aim of assessing the effects on cardiovascular risk indices in patients with subclinical hypothyroidism.
We conducted a randomized, double-blind, crossover study in a tertiary care setting.
Sixty patients with subclinical hypothyroidism participated in the study.
Patients were randomly assigned to either low-dose phytoestrogen (30 g soy protein with 2 mg phytoestrogens, representative of a Western diet) or high-dose phytoestrogen (30 g soy protein with 16 mg phytoestrogens, representative of a vegetarian diet) supplementation for 8 wk, then crossed over after an 8-wk washout period.
The primary outcome was progression to overt hypothyroidism, with secondary outcome measures of blood pressure, insulin resistance, lipids, and highly sensitive C-reactive protein (hsCRP).
Six female patients in the study progressed into overt hypothyroidism with a standardized rate ratio of 3.6 (95% confidence interval, 1.9, 6.2) after 16-mg phytoestrogen supplementation. Both systolic and diastolic blood pressure decreased with 16 mg phytoestrogens, whereas systolic pressure alone decreased with 2 mg phytoestrogens. Insulin resistance (homeostasis model assessment of insulin resistance, 3.5 ± 0.09 vs. 2.6 ± 0.08; P < 0.02) and hsCRP (4.9 ± 0.04 vs. 3.9 ± 0.03; P < 0.01) decreased with 16 mg phytoestrogens. Lipid profile remained unchanged.
There is a 3-fold increased risk of developing overt hypothyroidism with dietary supplementation of 16 mg soy phytoestrogens with subclinical hypothyroidism. However, 16-mg soy phytoestrogen supplementation significantly reduces the insulin resistance, hsCRP, and blood pressure in these patients.

1 Follower
  • Source
  • [Show abstract] [Hide abstract]
    ABSTRACT: Industrial chemical contaminants have a variable impact on the hypothalamic-pituitary-thyroid axis, this depending both on their class and on confounding factors. Today, mounting evidence is pointing to the role of environmental factors, and specifically EDCs, in the current distressing upsurge in the incidence of thyroid disease. The unease is warranted. These substances, which are nowadays rife in our environments (including in foodstuffs), have been shown to interfere with thyroid hormone action, biosynthesis, and metabolism, resulting in disruption of tissue homeostasis and/or thyroid function. Importantly, based on the concept of the "nonmonotonic dose-response curve", the relationship between dose and effect has often been found to be nonlinear. Thus, small doses can induce unpredictable, adverse effects, one case being polychlorinated biphenyls (PCBs), of which congener(s) may centrally inhibit the hypothalamic-pituitary-thyroid axis, or dissociate thyroid receptor and selectively affect thyroid hormone signaling and action. This means that PCBs can act as agonists or antagonists at the receptor level, underlining the complexity of the interaction. This review highlights the multifold activity of chemicals demonstrated to cause thyroid disruption. It also represents a call to action among clinicians to undertake systematic monitoring of thyroid function and registering of the classes of EDs and additionally urges broader scientific collaborations to clarify these chemicals' molecular mechanisms of action, substances whose prevalence in our environments is disrupting not only the thyroid but all life on earth.
    Endocrine 10/2014; 48(1). DOI:10.1007/s12020-014-0442-4 · 3.53 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Soyfoods have been a part of Asian diets for centuries. Today, there is a growing interest in these foods among westerners because of their proposed health benefits and also because their versatility makes them valuable for replacing meat and dairy foods in the diet. Nevertheless, the role of soyfoods in a healthy diet has become somewhat of a confusing issue in recent years because of concerns that these foods may exert adverse effects in some individuals. However, concerns about soyfoods are based almost entirely on the results from studies involving rodents. Results from rodent studies often don't predict effects in humans. Furthermore, because rodents metabolize soy much differently than humans, they aren't particularly useful models for learning about the effects of soyfoods [1]. Importantly, the human data are supportive of the safety and benefits of soyfoods. With the exception of those allergic to soy protein, which is relatively rare, all healthy individuals can safely consume soyfoods. Much of the concern about soy is based on the estrogen-like effects of isoflavones, a group of naturally-occurring plant chemicals that are found in large amounts in soybeans.